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Associations of Weight Change With Changes in Calf Muscle
Characteristics and Functional Decline in Peripheral Artery Disease
Tamar S. Polonsky, MD, MSCI; Lu Tian, ScD; Dongxue Zhang, MS; Lydia A. Bazzano, MD, PhD; Michael H. Criqui, MD, MPH; Luigi Ferrucci,
MD, PhD; Jack M. Guralnik, MD, PhD; Melina R. Kibbe, MD; Christiaan Leeuwenburgh, PhD; Robert L. Sufit, MD; Mary M. McDermott, MD
Background-—Among people with lower extremity peripheral artery disease, obesity is associated with faster functional decline
than normal weight. The association of weight loss with functional decline in peripheral artery disease is unknown.
Methods and Results-—Adults with an ankle-brachial index <0.90 were identified from Chicago-area hospitals in 2002–2004.
Weight and 6-minute walk distance were measured annually. Weight change categories were weight loss or gain (≥5 pounds/year
at ≥1 visit) or stable (weight change <5 pounds at each visit). Participants reported whether weight loss was “intentional” or
“unintentional.” Calf muscle area was measured with computed tomography every 2 years. Associations of weight change with
changes in calf muscle area and 6-minute walk distance were analyzed using mixed-effects models and adjusted for age, body
mass index, ankle-brachial index, physical activity, and other confounders. Among 389 participants, mean ankle-brachial index was
0.630.16, mean age was 74.57.8, and mean body mass index was 28.15.1 kg/m2. Over 3.231.37 years, muscle area
declined more in adults with intentional weight loss versus stable or gain (pair-wise comparisons, P<0.001). Intentional weight loss
was associated with less annual decline in 6-minute walk distance than weight gain (intentional loss, 3.7 m; stable, –14.0 m; gain,
28.5 m; unintentional loss, 20.8 m; pair-wise comparison intentional loss versus gain, P=0.003).
Conclusions-—Despite a greater loss of calf muscle area, adults with peripheral artery disease who intentionally lost ≥5 pounds
experienced less functional decline than those who gained weight. A randomized trial is needed to establish whether benefits of
weight loss in peripheral artery disease outweigh potential adverse effects. ( J Am Heart Assoc. 2019;8:e010890. DOI: 10.
1161/JAHA.118.010890.)
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P revalence of overweight or obesity is increasinglycommon among adults with peripheral artery disease
(PAD).1–4 Recent evidence demonstrated that >65% of adults
with PAD are overweight or obese.3–5 Among adults with PAD,
a higher body mass index (BMI) at baseline is associated with
more adverse changes in calf muscle characteristics over
time, greater functional decline, and a poorer response to
exercise training compared with normal weight adults with
PAD.1,6–11 In addition, adults with PAD who are overweight or
obese are more likely to require a lower extremity reavascu-
larization and experience a cardiovascular event than those
with a normal BMI.7,12
Whether weight loss or weight gain are also associated
with changes in lower extremity characteristics or functional
decline in PAD is not well understood. A previous study did
not show a significant association between weight loss or gain
with functional decline overall; however, adults who gained 5
to 10 pounds but exercised regularly had less functional
decline than adults who did not gain weight but also did not
exercise.13 An important consideration is whether or not
weight loss is intentional. Unintentional weight loss is often
marked by poor health status and frailty, thus potentially
confounding any association between weight change and
functional decline.14 For example, using data from the
Cardiovascular Healthy Study, Ix et al found an inverse
association between BMI and incident PAD in the whole
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cohort.1 However, after excluding adults who reported poor
health or unintentional weight loss, the researchers found a
positive association between BMI and incident PAD.
Given the high prevalence of overweight and obesity among
adults with PAD, it is important to understand the prognostic
implications of changes in weight.1–4 Therefore, the purpose of
these analyses was to delineate associations of changes in
weight with changes in calf muscle characteristics and
functional decline in PAD. We hypothesized that people with
PAD who lost weight intentionally would experience a greater
decline in muscle mass, but would experience less functional
decline than adults with PAD with unintentional weight loss, or
those whose weight remained stable or who gained weight.
Methods
The protocol for this study was approved by the institutional
review boards at Northwestern University Feinberg School of
Medicine (Chicago, IL) and by all participating centers. All
participants gave written informed consent. Methods have
been previously described.8,15 The data supporting the
findings of this study are available from the corresponding
author upon reasonable request, within constraints allowed by
the institutional review board.
Patient Identification
The study cohort was identified from participants who
completed baseline testing in the WALCS II (Walking and
Leg Circulation Study II) between May 2002 and May
2004.15–17 Participants were aged 59 years and older at
baseline. An ankle-brachial index (ABI) <0.90 was used as the
criterion to define PAD.
Data were collected between May 6, 2002 and October 16,
2009. Participants completed a baseline visit and up to 4
annual follow-up visits. Calf muscle characteristics were
measured by computed tomography (CT) at baseline and at 2-
and 4-year follow-up assessments. Functional outcomes were
measured at baseline and at each annual follow-up visit.
Exclusion Criteria
Exclusion criteria have been described previously and are
summarized here.16 Participants with dementia, recent major
surgery, or lower extremity amputations were excluded.
Nursing home residents and wheelchair-bound participants
were excluded. Non-English-speaking participants were
excluded because investigators were not fluent in non-English
languages.
Ankle-brachial Index
ABI was measured at the baseline visit, using established
methods.18,19 Systolic blood pressures in the right and left
brachial, dorsalis pedis, and posterior tibial arteries were
obtained using a handheld Doppler probe (Vascular Pocket
Dop II; Nicolet, Golden, Colo), and each pressure was
measured twice.18,19 The ABI was calculated for each leg by
dividing the mean of the dorsalis pedis and posterior tibial
pressures by the mean of the 4 brachial pressures. When the
brachial pressure in 1 arm was higher than in the opposite
arm, and the 2 brachial pressures differed by 10 mm Hg, the
arm with highest pressure was used in the denominator for
ABI calculation because subclavian stenosis was potentially
present in these instances.20 The ABI for the leg with the
lowest ABI was used in the statistical analyses for calf muscle
characteristics.
Weight and Weight Change
Weight was measured at baseline and all annual follow-up
visits. BMI was calculated as weight (kilograms) divided by
height (meters) squared. All weight change refers to annual
change. Weight loss was defined as ≥5-pound decrease and
weight gain was defined as ≥5-pound increase compared with
the previous year’s visit, at 1 or more of the follow-up visits.
Stable weight was defined as any weight change from the
previous year that was <5 pounds at all visits.
We chose a 5-pound cutoff for weight loss or gain because
it could be clinically meaningful, but also more easily
achievable without a formal weight-loss program. In addition
Clinical Perspective
What Is New?
• Adults with peripheral artery disease with ≥5 pounds
intentional weight loss experienced less annual decline in
the 6-minute walk than adults who gained ≥5 pounds.
• The slower decline in 6-minute walk occurred despite a
significantly greater reduction in muscle area among those
who lost weight compared with those who gained weight.
• There was no difference between groups in knee extension
strength or power.
What Are the Clinical Implications?
• Prevalence of overweight or obesity among adults with
peripheral artery disease is as high as 75%, and yet clinical
practice guidelines do not address treatment of overweight
or obesity.
• Encouraging weight loss may help mitigate functional
decline among adults with peripheral artery disease.
• However, a clinical trial is needed to demonstrate that the
benefits outweigh potential harms.
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to measuring weight at each visit, participants were asked
whether they experienced at least a 5-pound weight loss
between visits. For those who responded that they had lost
≥5 pounds, their weight loss was categorized as “intentional”
or “unintentional” based on their response to the following
question: “Was the weight loss intentional, that is, were you
trying to lose the weight?” The question was asked starting at
follow-up visit 2, and so data about whether or not weight loss
was intentional are not available at baseline and follow-up visit
1. Participants were only classified as having lost weight if
their measured weight between study visits decreased by ≥5
pounds. Participants who reported weight loss but whose
measured weight at follow-up visits did not decrease by ≥5
pounds were classified based on their measured weight.
Calf Muscle Characteristics
Calf muscle characteristics were measured at baseline and
every 2 years using a CT scanner (LightSpeed; General
Electric Medical Systems, Waukesha, WI) and BonAlyse
software (BonAlyse OY, Jyvaskyla, Finland).17,21 Cross-sec-
tional CT images (2.5-mm) of the calves were obtained at
66.7% of the distance from the distal to the proximal tibia, the
point of maximal muscle cross-sectional area.22 Scanned
images were analyzed by BonAlyse software, which distin-
guishes between muscle tissue, fat, and bone by detecting
different density thresholds, using the density of water as the
reference. Bone and subcutaneous fat were excluded from
analyses. Muscle area was quantified by summing voxels
within the range corresponding to muscle density (9–
271 mg/cm3). Intramuscular fat was quantified by summing
voxels corresponding to fat tissue (270 to 8 mg/cm3). This
method of estimating muscle area has been validated through
previous cadaveric studies and is shown to be highly
correlated with direct anatomical measurements.22
Leg Strength and Muscle Power
Isometric knee extension strength and knee extension power
were measured at baseline and at each annual follow-up visit.
Isometric knee extension strength was assessed using the
Good Strength Chair (Metitur Oy, Jyvasklya, Finland).23,24
Participants were seated in the chair and instructed to push
against secure leg attachments for 5 seconds. The leg
attachments were fixed with strain gauges that were linked
by transducers to a computer that recorded the measure-
ments. From 2 trials, the highest value was used.
Knee extension power was assessed using a power rig.24,25
Participants were seated with their arms folded across the
chest and asked to push a footplate that was connected to a
flywheel. The final velocity of the flywheel was measured by
an optoswitch attached to a microcomputer, from which
average power could be derived. Each push lasted between
0.20 and 0.40 seconds, and up to 10 consecutive trials were
used to obtain maximum power.
Six-Minute Walk Test
In the 6-minute walk test, participants walked back and
forth along a 100-foot hallway with instructions to cover as
much distance as possible, based on previously described
methods.26,27
Comorbidities
Participant comorbidities were identified using algorithms
from the Women’s Health and Aging Study and Cardiovascular
Health Study, which combined data from patient report,
physical examination, medical record review, medications,
laboratory values, and a primary care physician question-
naire.28 These criteria were used to document angina, cancer,
diabetes mellitus, heart failure, myocardial infarction, pul-
monary disease, stroke, spinal stenosis, and disk disease.
American College of Rheumatology criteria were used to
diagnose knee and hip arthritis.29
Walking Exercise Activity
During each study visit, participants were asked, “During the
past 2 weeks, have you gone walking for exercise?” Fre-
quency and duration of walking for exercise were also
determined at each visit. Based on earlier studies, a minimum
frequency of 3 times per week and a minimum duration of
30 minutes per session are most optimal for supervised
walking exercise programs in patients with PAD.30 Therefore,
participants were classified as exercising regularly if they
walked ≥3 times for ≥30 minutes per session, per week.
During each study visit, participants were also asked how
many blocks they had walked in the past week.
Other Measures
Occurrence of lower extremity revascularization and hip or
knee replacement surgery during follow-up was obtained by
patient report and ascertained by medical record review or a
primary care physician questionnaire. Cigarette smoking was
assessed by patient report. Medication use was assessed at
each study visit. Participants brought their medication bottles
or a list of medications to their study visit. The study principal
investigator (M.M.M.) and study first author (T.S.P.) identified
which participants were taking statin, antiplatelet medication
(aspirin or clopidogrel), and cilostazol, blinded to participant
characteristics. We used the Social Security Administration
Death Index to search for deaths through May 23, 2009.
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Information on deaths was also obtained from family mem-
bers, proxies, and primary care physicians.
Statistical Analyses
Participants were included in the analyses if they returned for
at least 1 follow-up visit. Over the course of the study,
participants may have met criteria for more than 1 weight
change category. However, when calculating baseline char-
acteristics, participants were classified into mutually exclusive
categories. Adults who met the criterion for weight loss at ≥1
follow-up visit, but also met the criterion for weight gain at
other follow-up visits were classified as “fluctuate.” Partici-
pants who lost weight at ≥1 visit, and whose weight remained
stable at other study visits, were classified as having lost
weight. Participants who gained weight at ≥1 visit, and whose
weight remained stable at other study visits, were classified
as having gained weight. Baseline characteristics across
weight change categories (weight loss, weight gain, stable,
and fluctutate) were compared using general linear regression
models for continuous variables and chi-square test for
categorical variables. When analyzing baseline characteristics,
participants with weight loss were not stratified by intentional
versus unintentional, because the question was only included
in the study protocol starting at the second follow-up visit.
Agreement between reported and measured weight loss of ≥5
pounds was assessed using the kappa statistic.
To compare annual changes in 6-minute walk, calf muscle
characteristics, knee extension strength, and knee extension
power, the mixed-effects linear regression analysis was used
with a subject-specific random intercept. This accounted for
the possibility that each participant’s annual change in
outcomes was correlated with their previous annual change.
The weight change categories for annualized changes in lower
extremity outcomes were intentional weight loss, uninten-
tional weight loss, stable weight, and weight gain. The
fluctuate category was excluded from the longitudinal anal-
yses because the regression was based on weight changes
between successive annual visits. For analyses involving
intentional versus unintentional weight loss, the changes in
outcomes from baseline to first annual follow-up were
excluded, because participants were not asked whether their
weight loss was intentional until the second follow-up visit.
Annual increments of weight change were analyzed (rather
than longer-term changes) given the likelihood that the largest
association with 6-minute walk and knee extension strength
and power would likely occur in close proximity to the weight
changes. Because CT scans were performed every 2 years,
participants were classified based on the 2-year net change in
weight for analyses related to calf muscle area and percent
fat. For example, if a participant lost 6 pounds intentionally
between the first and second follow-up visits, but gained 4
pounds between the second and third follow-up visits (net 2-
year weight loss of 2 pounds), then the participant would be
classified as having stable weight for the CT measures only.
However, for the 6-minute walk and knee extension strength
and power, which were measured annually, the participant
would contribute 1 person-year each to the intentional weight
loss and stable weight categories.
Person-years for each weight change category were
summed from the successive annual changes at each
follow-up visit. The number of person-years a participant
contributed depended on how long they remained with the
study. Some participants contributed person-years to more
than 1 weight change category (eg, weight loss between
baseline and the first follow-up visit, but weight stable
between the first and second visits). Skipped interim visits
were handled as missing data. Annual weight change was not
calculated for skipped visits. Time between consecutive visits
was not included as a covariate.
Dependent variables were the successive changes in 6-
minute walk distance, calf skeletal muscle characteristics, leg
strength, and power. Analyses were adjusted for age, race,
sex, BMI, ABI, smoking, comorbidities, regular exercise, the
number of blocks walked per week, medication use (aspirin or
clopidogrel, statin, and cilostazol), tibia length (muscle area
and knee extension measures only), lower extremity revascu-
larization during follow-up, hip or knee replacement during
follow-up, presence of arthritis, and previous year muscle
measure (for muscle outcomes) or previous year functional
performance (for functional outcomes) or previous leg
strength and power measures (for leg strength and power
outcomes). For the outcome of the 6-minute walk, we also
evaluated results without adjustment for physical activity and
medication use.
Results
Four hundred sixty-three participants with PAD completed
baseline testing in the WALCS II cohort. Thirty-eight partic-
ipants were excluded because they did not attend a follow-up
visit. An additional 36 participants who attended a follow-up
visit were excluded because of missing baseline information
or outcome data. Ultimately, 389 participants who completed
at least 1 follow-up visit were included in analyses. Mean
follow-up was 3.231.37 years.
Mean age was 74.87.8 years, and mean ABI was
0.630.16. Table 1 shows participant characteristics accord-
ing to weight change category. Mean BMI was in the
overweight range in all groups, with prevalence of overweight
or obesity ranging from 65% in the stable weight category to
81% in the fluctuate group. Compared with PAD participants
with stable weight, those who lost ≥5 pounds during follow-up
included a higher prevalence of men and a higher baseline
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prevalence of cancer. Participants who gained weight had a
higher baseline prevalence of diabetes mellitus, angina, and
myocardial infarction and black race. The number of partic-
ipants who attended each follow-up visit are shown in Figure.
Overall, 164 (42.2%) of the 389 participants attended all
follow-up visits. There were no deaths between the baseline
visit and the first follow-up visit; 63 participants (16.2%) died
during follow-up.
Table 2 includes a comparison of baseline characteristics
between those who were included in the analyses, those who
were excluded because they did not attend any follow-up
visits, and those who attended follow-up visits but were
excluded because of missing baseline information or outcome
data. Adults who were excluded were slightly older, were
more likely to have pulmonary disease, and had a smaller calf
area than those who were included. Mean BMI was >25 kg/m2
in all 3 categories.
There was moderate correlation between self-report of
weight loss ≥5 pounds and whether the participant actually lost
≥5 pounds based on measured weights at follow-up visits
(kappa, 0.43; Table 3). Participants with PAD reported weight
loss of ≥5 pounds over 233 person-years. Of these, there were
122 (52%) person-years in which participants had measured
weight loss ≥5 pounds, consistent with their report. There were
180 person-years in which participants had a measured weight
loss of ≥5 pounds at ≥1 follow-up visits. Over 122 of 180 (68%)
person-years, participants responded “yes” to the question,
“Since your most recent WALCS visit, have you lost 5 or more
pounds of weight?” For the remaining 58/180 person-years,
the participants had responded that they had not lost weight
and so were classified as unintentional weight loss given that
they did not recognize that they had lost weight.
The magnitude of weight change, stratified by annual
weight change category and BMI, is shown in Table 4. Among
Table 1. Baseline Characteristics of Participants With Peripheral Artery Disease According to Weight Change Category During
Follow Up (n=389)
Variable Loss (n=136) Stable (n=108) Gain (n=67) Fluctuate (n=78) P Value
Age, y 75.5 (6.7) 75.0 (8.0) 72.6 (8.7) 73.5 (8.2) 0.04
Male, % 58.1 53.7 46.3 56.4 0.44
Black, % 16.9 15.7 19.4 15.4 0.91
Ankle-brachial index 0.63 (0.15) 0.63 (0.16) 0.61 (0.16) 0.65 (0.16) 0.63
Baseline BMI, kg/m2 28.11 (4.80) 26.80 (4.54) 28.05 (5.62) 29.74 (5.37) 0.002
Overweight, % 43 43 46 36 0.61
Obese, % 31 22 28 45 0.01
Mean weight change during study, pounds (SD)
Mean weight loss 10.25 (5.93) n/a n/a 12.46 (8.83) 0.02
Mean weight gain n/a n/a 9.76 (5.89) 9.58 (7.08) 0.85
Mean number of visits with weight change 1.22 n/a 1.12 2.55 0.001
Diabetes mellitus, % 30.88 29.63 40.30 34.62 0.47
Angina, % 33.33 37.14 40.30 29.87 0.55
Myocardial infarction, % 22.79 26.85 38.81 22.08 0.07
Stroke, % 19.85 26.85 19.40 15.38 0.27
Lower extremity arthritis, % 18.4 15.7 17.9 19.2 0.87
Pulmonary disease, % 44.85 39.81 41.79 44.87 0.96
Cancer, % 26.47 15.74 8.96 24.36 0.013
Calf muscle
Area, mm2, SD 5602 (1309) 5474 (1543) 5273 (1512) 5583 (1386) 0.46
Percentage of fat, % 9.55 (8.68) 9.87 (12.57) 14.48 (17.48) 12.13 (13.73) 0.047
Isometric knee extension strength, N 274.56 (108.60) 283.99 (113.66) 263.07 (103.06) 280.97 (119.15) 0.77
Knee extension power, W 96.02 (50.52) 93.85 (48.57) 88.02 (60.00) 104.65 (53.01) 0.32
Six-minute walk distance, meters 351.37 (105.49) 342.05 (118.06) 331.92 (146.26) 337.61 (129.88) 0.72
Values are expressed asmean (SD), unless otherwise indicated. Stable, weight change within 5 pounds in all visits; Loss, lost ≥5 pounds at least 1 visit and never gained ≥5 pounds; Gain, gained
≥5 pounds at least 1 visit and never lost 5 or more pounds; Fluctuate, both lost and gained ≥5 pounds throughout course of study. BMI indicates body mass index; n/a, not applicable.
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participants who gained weight, the amount of annual weight
gain was similar regardless of the previous year’s BMI, and
ranged from 8.8 to 10.7 pound. Adults who were obese and
lost weight intentionally lost larger amounts of weight
(17.511.7 pounds) compared with obese participants with
unintentional weight loss (12.99.6 pounds). Degree of
weight loss among overweight participants was similar
between those with intentional (9.84.0 pounds) and unin-
tentional weight loss (9.96.1 pounds).
Additional potential confounders of the association
between weight change and lower extremity outcomes are
shown in Table 5. Use of statins, aspirin, clopidogrel, or
cilostazol was similar in the 4 weight change categories.
Regular walking exercise was uncommon among participants
in all weight change categories. However, adults with
intentional weight loss walked more blocks in the past week
than other categories.
In multivariable analyses, PAD participants with intentional
weight loss had the smallest decline in the 6-minute walk
(model 3, intentional loss +3.7 m; weight stable, 14.0 m;
weight gain, 28.5 m; unintentional loss, 20.8 m; Table 6).
In the fully adjusted pair-wise comparisons, there was a
Baseline visit, n=463 
Study procedures:
Medical history, medication use
Self-reported physical activity
Ankle-brachial index testing (ABI)
Six-minute walk test
Leg strength and power
Lower extremity computed 
tomography (CT)
N=389 included in the analyses
Follow-up visit 1, n=374
Study procedures:
Medical history, medication use
Self-reported physical activity
ABI
Six-minute walk test
Leg strength and power
Follow-up visit 2, n=321
Study procedures:
Medical history, medication use
Self-reported physical activity
ABI
Six-minute walk test
Leg strength and power
Lower extremity CT
Follow-up visit 3, n=238
Study procedures:
Medical history, medication use
Self-reported physical activity
ABI
Six-minute walk test
Leg strength and power
Follow-up visit 4, n=194
Study procedures:
Medical history, medication use
Self-reported physical activity
ABI
Six-minute walk test
Leg strength and power
Lower extremity CT
65 missing weight information
5 missing outcomes
4 missing baseline information for one or more covariates
13 deaths, 
2 drop out
38 missing outcomes
27 deaths, 
11 drop out
45 missing outcomes
22 deaths, 
5 drop out
17 missing outcomes
0 death 
0 drop out
15 missing outcomes
Figure. Study flow, walking, and leg circulation study.
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significant difference in the annual change in 6-minute walk
between intentional versus unintentional weight loss
(P=0.022) and intentional weight loss versus weight gain
(P=0.003), but not those with intentional weight loss versus
stable weight (P=0.067).
In pair-wise comparisons, adults with intentional weight
loss had a significantly greater decrease in muscle area than
adults who gained weight and whose weight was stable
(P<0.001 for both). There was no significant difference in the
change in calf muscle area between those with intentional
versus unintentional weight loss. In pair-wise comparisons,
the increase in percent fat, and the change in knee extension
strength and power among adults with intentional weight loss,
was not significantly different from the other groups.
Associations of clinical characteristics with annual change
in 6-minute walk are shown in Table 7. Adults with uninten-
tional weight loss were excluded, given that the association
between unintentional weight loss and change in 6-minute
walk was so different from that of intentional weight loss. In a
multivariable regression analysis, age, male sex, current
smoking, and a higher baseline BMI were significantly
associated with decline in the 6-minute walk. With regard to
weight change, for every pound gained there was an
additional decline in the 6-minute walk distance by 0.96 m.
Discussion
In this longitudinal, observational cohort of 389 adults with
PAD, almost three-quarters (71%) of the participants were
Table 2. Comparison of Baseline Characteristics Among Participants Who Were Included and Excluded From the Analyses
Variable Included (N=389)
Excluded: Did Not Attend Any
Follow-up Visits (N=38)
Excluded: Attended Follow-up
Visits but Had Missing Data (N=36) P Value
Age, y (SD) 74.5 (7.8) 78.2 (10.3) 77.3 (9.9) 0.006
Male, % 54.5 50.0 44.4 0.47
Black, % 16.7 13.2 25.0 0.36
Ankle-brachial index, (SD) 0.63 (0.16) 0.63 (0.15) 0.62 (0.18) 0.96
Baseline BMI, kg/m2 (SD) 28.1 (5.1) 25.9 (4.1) 27.6 (6.0) 0.059
Overweight, % 42.2 42.9 25.0 0.16
Obese, % 30.8 14.3 37.5 0.078
Diabetes mellitus, % 32.9 29.0 30.6 0.86
Angina, % 34.9 46.0 28.6 0.28
Myocardial infarction, % 26.5 31.6 19.4 0.49
Stroke, % 20.8 29.0 22.2 0.51
Lower extremity arthritis, % 15.9 7.9 13.9 0.41
Pulmonary disease, % 42.9 47.4 50.0 0.012
Cancer, % 20.1 18.4 19.4 0.97
Calf muscle
Area, mm2 (SD) 5505.5 (1428.3) 5102.2 (996.2) 4757.5 (1624.9) 0.005
Percentage of fat, % (SD) 11.0 (12.8) 8.4 (7.1) 16.2 (15.2) 0.030
Isometric knee extension strength, N, (SD) 276.8 (111.1) 252.1 (102.3) 256.8 (121.0) 0.45
Knee extension power, W, (SD) 95.8 (52.2) 70.1 (36.0) 90.9 (66.8) 0.032
Six-minute walk distance, meters, (SD) 342.8 (121.3) 310.9 (124.8) 306.1 (107.9) 0.13
BMI indicates body mass index.
Table 3. Associations of Actual vs Self-Reported Weight Loss
Among People With Peripheral Artery Disease (n=720 visits)
Self-Reported Weight Loss
Yes No Total Person-Years
Actual weight loss
Yes (total %) 122 (16.9) 58 (8.1) 180
Row % 68 32
Column % 52 12
No 111 (15.4) 429 (59.6) 540
Row % 21 79
Column % 48 88
Total person-years 233 487 720
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overweight or obese. The high prevalence of overweight or
obesity in the current study is similar to the prevalence in
population-based cohorts, and suggests that an important
component of treatment for PAD should address obesity.2–4
We found that adults with PAD who intentionally lost weight
had significantly less decline in 6-minute walk performance,
compared with participants with PAD who gained weight or
who had unintentional weight loss. The substantially smaller
decline in 6-minute walk distance among people with
intentional weight loss occurred despite greater declines in
calf muscle area compared with participants who maintained
stable weight or who gained weight. The pair-wise compar-
isons between intentional weight loss and weight gain and
unintentional weight loss remained statistically significant and
were even stronger after adjusting for physical activity. A key
finding of this study is that, with regard to changes in weight,
the change in 6-minute walk is not consistent with changes in
muscle characteristics. These results also highlight that adults
with unintentional weight loss represent a vulnerable popu-
lation, given that the magnitude of decline in the 6-minute
walk was similar to that of adults who gained weight.
To our knowledge, no previous studies have assessed
associations between changes in body weight, lower extremity
muscle characteristics, and function among people with PAD.
However, several randomized, controlled trials of weight loss
in obese older adults without PAD have shown favorable
effects on functional performance. For example, in a random-
ized trial of 93 obese adults aged ≥65 years, those randomized
to calorie restriction lost 9.05.4 kg and experienced a
significantly greater improvement in multiple measures of
physical function, including peak oxygen consumption, gait
speed, and balance, compared with the control group, despite
a decrease in muscle mass.31 In the third arm of the trial,
which combined exercise and diet, exercise attenuated, but
did not completely mitigate, muscle and bone loss observed
with weight loss. An analysis of 3 weight-loss trials that
incorporated calorie restriction with physical activity showed
that every 1-kg loss of fat mass predicted a 0.01-m/s increase
in walking speed, independent of loss of lean mass.32 In
another weight-loss trial, Villareal et al demonstrated that
older adults randomized to resistance plus aerobic exercise
experienced less decline in muscle mass than those random-
ized to aerobic or resistance training alone.33
There are several potential explanations for why intentional
weight loss could mitigate functional decline observed in PAD,
despite a decrease in muscle area. Weight loss may simply
Table 4. Mean Weight Change Between Annual Follow-up Visits, Stratified by Weight Change Category and BMI (N=1003 visits)*
Previous Year BMI
Weight Change Among Those
With Intentional Weight Loss
Weight Change Among Those
With Unintentional Weight Loss
Weight Change Among
Those With Stable Weight
Weight Change Among
Those With Weight Gain
BMI 18 to <25, pounds
of weight loss (SD)
14.3 (–) 7.7 (1.9) 0.2 (2.6) 10.7 (7.8)
1 person-year 37 person-years 192 person-years 38 person-years
BMI 25 to <30, pounds
of weight loss (SD)
9.8 (4.0) 9.9 (6.1) 0.1 (2.7) 8.8 (3.9)
18 person-years 52 person-years 278 person-years 61 person-years
BMI ≥30, pounds of
weight loss (SD)
17.5 (11.7) 12.9 (9.6) 0.1 (2.8) 9.8 (7.7)
24 person-years 48 person-years 180 person-years 74 person-years
BMI indicates body mass index.
*Person-years with missing data regarding intentional/unintentional weight loss were excluded.
Table 5. Annual Medication Use and Annual Self-Reported Measures of Physical Activity Among Adults With Peripheral Artery
Disease
Intentional Weight Loss Weight Stable Weight Gain Unintentional Weight Loss
Statin use, n (%) 29 (61.7)
47 person-years
408 (63.6)
642 person-years
93 (53.1)
175 person-years
99 (67.8)
146 person-years
Aspirin or clopidogrel
use, n (%)
36 (76.6)
47 person-years
417 (65.0)
642 person-years
115 (65.7)
175 person-years
95 (65.1)
146 person-years
Cilostazol use, n (%) 4 (8.5)
47 person-years
63 (10.1)
622 person-years
19 (11.2)
170 person-years
14 (9.6)
146 person-years
Walking ≥30 min for ≥3
days a week, n (%)
12 (25.5)
47 person-years
121 (18.8)
644 person-years
24 (13.6)
177 person-years
25 (17.0)
147 person-years
Mean number of blocks
walked per week, (95% CI)
32.3 (18.5, 46.1)
47 person-years
28.3 (24.2, 32.3)
622 person-years
23.7 (17.1, 30.3)
170 person-years
21.5 (13.4, 29.6)
146 person-years
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improve exercise capacity because of the reduction in work
required for physical activity.34 However, in a study of
treadmill testing in 46 adults with PAD, total exercise time
and oxygen consumption were similar in the obese and
nonobese participants.9 And yet, based on serial ABI testing,
adults with obesity experienced a slower recovery after
exercise than nonobese adults, suggesting that obesity has a
direct effect on muscle perfusion. Mouse models have shown
impaired nitric-oxide-dependent vasodilation and enhanced
vasoconstriction in the hind limb of obese versus nonobese
mice.35 Inflammation contributes to exercise limitation in PAD
and may be further exacerbated by obesity.35–40 Mouse
models of obesity demonstrate an expansion of fat between
and around skeletal muscle fibers, with an accumulation of
proinflammatory macrophages and T cells.36 Adipose tissue is
also a source of inflammatory cytokines, such as interleukin
(IL)-6 and tumor necrosis factor (TNF)-a, that have direct
adverse effects on muscle; TNF-a impairs muscle protein
synthesis and increases muscle protein degradation whereas
IL-6 increases muscle protein degradation.41 It has also been
demonstrated that TNF-a impairs endothelial function with a
decreased blood and nutrient supply to skeletal muscle, thus
reducing exercise endurance.39 Finally, obesity may worsen
functional decline in PAD through pathways involving mito-
chondrial function. A high-fat diet has been shown to
downregulate genes responsible for mitochondrial biogenesis
and function.42 Visceral fat promotes insulin resistance, which
then promotes muscle catabolism, impaired protein synthesis,
and mitochondrial dysfunction.33
It is also important to consider that other studies suggest
that measurement of isotope-labeled creatine more accu-
rately reflects muscle mass than estimates based on muscle
area by CT.43 In addition, previous studies have shown only a
moderate correlation between muscle area and function,
which may explain why we observed a decrease in muscle
area, but an improvement in the 6-minute walk distance.44
Our study has limitations. First, the proportion of partic-
ipants who intentionally lost weight was small, and so we only
evaluated modest amounts of weight loss. The results may
have differed with larger changes in weight or with a larger
proportion of adults who lost weight intentionally. It is
possible that we lacked power to detect significant differ-
ences in knee strength or power and percent of fat in the calf
muscle in the pair-wise comparisons. Second, there was only
moderate correlation between actual weight loss and self-
report of weight loss. It is possible that participants had lost
weight, but then already regained it by their study visit. It is
also possible that some of the participants lost weight
because of treatment with diuretics, rather than a decrease in
adiposity. Third, we did not objectively measure physical
activity on all participants. However, the pair-wise compar-
isons for 6-minute walk were strengthened after adjustment
for self-reported physical activity. Furthermore, previous
randomized, controlled trials of exercise programs in older
Table 7. Associations of Clinical Variables With Annual Change in 6-Minute Walk Among Adults With Peripheral Artery Disease*
Variable
Annual Change in 6-Minute Walk (m)
(95% CI) P Value
One-year change in weight (per 1-pound increase) 0.96 (1.58, 0.35) 0.002
Previous year’s 6-minute walk (m) 0.11 (0.15, 0.07) <0.0001
Age (per y increase) 1.13 (1.62, 0.65) <0.0001
Male (yes vs no) 10.76 (3.05, 18.47) 0.006
Black (yes vs no) 2.59 (11.98, 6.81) 0.59
Smoking (yes vs no) 12.25 (23.00, 1.50) 0.026
ABI (per 0.1 unit increase) 11.81 (10.87, 34.49) 0.31
Baseline body mass index (per 1 unit higher) 1.41 (2.24, 0.58) 0.001
Number of blocks walked per week 0.01 (0.05, 0.07) 0.73
Cancer (yes vs no) 0.41 (8.96, 8.14) 0.92
Diabetes mellitus (yes vs no) 1.68 (9.62, 6.27) 0.68
Pulmonary disease (yes vs no) 5.25 (12.27, 1.77) 0.14
Previous myocardial infarction, angina, heart failure, or stroke (yes vs no) 1.27 (4.38, 1.83) 0.42
Arthritis (yes vs no) 0.07 (4.58, 4.44) 0.98
Previous lower extremity revascularization (yes vs no) 11.36 (3.83, 26.55) 0.14
Lower extremity revascularization during follow-up (yes vs no) 10.46 (3.56, 24.48) 0.14
*Adults with unintentional weight loss were excluded. ABI indicates ankle-brachial index.
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adults have shown that exercise alone does not lead to
substantial weight loss.31,45 Fourth, the cohort included PAD
participants aged 59 years and older. Further study is needed
to determine whether the results are generalizable to younger
people with PAD. Fifth, only 42% of participants attended all 4
exams. However, our focus on annualized changes in lower
extremity outcomes with changes in weight, rather than long-
term changes, should have minimized the effect on our
results.
Conclusion
Among adults with PAD, intentional weight loss was associ-
ated with less functional decline than adults who gained
weight, despite adverse changes in muscle area. Although
walking exercise remains the foundation of treatment for PAD,
adults who are overweight or obese do not respond to walking
exercise as well as adults who are normal weight. Given the
high prevalence of overweight and obesity in PAD, future
study with a randomized trial is needed to establish defini-
tively the effects of weight loss in addition to exercise on
lower extremity outcomes in PAD.
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